More on BLSM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $14.16 |
|
|||
| Open | $14.09 | ||||
| 52 Wk High | $1.85 | ||||
| 52 Wk Low | $0.80 | ||||
| Day High | $15.05 | ||||
| Day Low | $14.09 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 74,925 | ||||
- H.C. Wainwright Reiterates Buy Rating on BlossomHill Therapeutics (BLSM)
- BlossomHill shares preclinical data on pan-KRAS inhibitor BH-501284
- BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
- BlossomHill Therapeutics (BLSM) PT Raised to $40 at Guggenheim
- Form 10-Q BlossomHill Therapeutics For: Jun 30
- Form 8-K BlossomHill Therapeutics For: Sep 18
- BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
- Form 8-K BlossomHill Therapeutics For: Sep 15
- BlossomHill drug shows 45% response rate in hard-to-treat lung cancer
- BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASL
Entities mentioned with BLSM
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- IPO | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Guggenheim | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
